Another example is Cabozantinib, a TKI of c-MET/VEGF receptor 2 (VEGFR2), is undergoing a phase III valuation in HCC patients who not tolerate or did failed treatment with sorafenib (Verslype et al., 2012). The gene discussed is MET; the disease is hepatocellular carcinoma.